0000000000681359

AUTHOR

Christoph Rohde

showing 4 related works from this author

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.

2019

CLDN18.2 expression is highly prevalent in Japanese patients with gastric cancer, making it a targetable alteration, and supporting development of zolbetuximab as a therapeutic agent for this patient population.

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentPopulationprevalenceAdenocarcinomaGastroenterologyAsian PeopleStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingeducationLymph nodeIMAB362Chemotherapyeducation.field_of_studybiologybusiness.industrygastric cancerCancerAntibodies MonoclonalbiomarkersGeneral Medicinemedicine.diseaseImmunohistochemistryClaudinGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyLymphatic MetastasisClaudinsbiology.proteinImmunohistochemistryBiomarker (medicine)Original ArticleAntibodybusinessJapanese journal of clinical oncology
researchProduct

Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals

2011

Claudin-18 isoform 2 (CLDN18.2) is one of the few members of the human claudin family of tight junction molecules with strict restriction to one cell lineage. The objective of the current study was to compare molecular structure and tissue distribution of this gastrocyte specific molecule in mammals. We show here that the CLDN18.2 protein sequence is highly conserved, in particular with regard to functionally relevant domains in mouse, rat, rabbit, dog, monkey and human and also in lizards. Moreover, promoter regions of orthologs are highly homologous, including the binding site of the transcription factor cyclic AMP-responsive element binding protein (CREB), which is known to regulate acti…

Gene isoformmiceMolecular Sequence DataGene Expressionmolecular structureMammals/geneticsBiologyphylogenyRATSConserved sequenceEvolution MolecularDogsProtein Isoforms/geneticsSequence Homology Nucleic AcidGene expressionGeneticsProtein IsoformsAnimalsTissue DistributionAmino Acid SequenceMembrane Proteins/geneticsBinding sitePromoter Regions GeneticClaudinGeneTranscription factorConserved SequenceGastric Mucosa/metabolismMammalsRegulation of gene expressionGeneticsBinding SitesBase SequenceStomachStomach/cytologyMembrane ProteinsCREB-Binding Protein/metabolismHaplorhiniGeneral MedicineCREB-Binding ProteinGene Expression RegulationGastric MucosaOrgan SpecificityMultigene FamilyClaudinsRabbitsGene
researchProduct

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

2018

Introduction IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a potent, targeted immunotherapeutic agent. Methods This first-in-human phase I study enroled adult patients (N = 15) with advanced gastric or gastro-oesophageal junction cancer into five sequential single dose-escalation cohorts (33, 100, 300, 600, and 1000 mg/m2) following a 3 + 3 design. Safety/tolerability, including determination of maximum tolerated dose and recommended phase II dose, were the pr…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyTime FactorsEsophageal NeoplasmsMaximum Tolerated Dosemedicine.medical_treatmentMedizinGastroenterologyAntibodies Monoclonal/administration & dosage03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalPharmacokineticsAntineoplastic Agents Immunological/administration & dosageStomach NeoplasmsInternal medicineGermanymedicineHumansDrug Dosage CalculationsAdverse effectInfusions IntravenousAgedbusiness.industryCancerAntibodies MonoclonalEsophagogastric Junction/drug effectsImmunotherapyMiddle Agedmedicine.diseaseLatviaddc:030104 developmental biologyTreatment OutcomeOncologyTolerabilityResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisToxicityDisease ProgressionFemaleStomach Neoplasms/drug therapyEsophagogastric JunctionEsophageal Neoplasms/drug therapybusinessProgressive disease
researchProduct

High Prevalence of Claudin 18.2 Expression in Japanese Patients with Gastric Cancer.

2017

e15584 Background: Expression of the gastric mucosal tight junction protein, Claudin-18.2 (CLDN18.2), is altered in gastric cancer (GC). In a phase 2 clinical trial (NCT01630083; FAST), a monoclonal antibody against CLDN18.2 (IMAB362) significantly increased overall survival in European patients with CLDN18.2-positive (CLDN18.2+) gastric and gastroesophageal junction adenocarcinomas when added to an EOX chemotherapy regimen. As the GC occurrence is high in Japan, this study evaluated the prevalence of CLDN18.2 expression in Japanese patients with GC. Methods: CLDN18.2 expression was assessed in primary GC tumors and corresponding lymph node metastases (LNM) by cell membrane staining intens…

Cancer ResearchHigh prevalenceOncologyTight junctionbusiness.industryMonoclonalmedicineCancer researchPhases of clinical researchCancerClaudinmedicine.diseasebusinessJournal of Clinical Oncology
researchProduct